B. Hudson

发表

The Clinical and Prognostic Relevance of Histopathologic Classification in Hodgkin’s Disease

K. Maclennan, G. Hudson, M. Bennett, 1989 .

The pretreatment peripheral blood lymphocyte count in 1100 patients with Hodgkin's disease: the prognostic significance and the relationship to the presence of systemic symptoms.

K. Maclennan, J. Haybittle, A. Jelliffe, 1981, Clinical oncology.

Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin's disease. A study of 1659 patients

K. Maclennan, M. Easterling, B. Hudson, 1989, Cancer.

Prognostic significance of cytologic subdivision in nodular sclerosing Hodgkin’s disease: An analysis of 1156 patients

K. Maclennan, M. Easterling, A. Jelliffe, 1985 .

REVIEW OF BRITISH NATIONAL LYMPHOMA INVESTIGATION STUDIES OF HODGKIN'S DISEASE AND DEVELOPMENT OF PROGNOSTIC INDEX

K. Maclennan, J. Haybittle, F. Hayhoe, 1985, The Lancet.

Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation.

K. Maclennan, A. Swerdlow, A. Douglas, 1992, BMJ.

Non-Hodgkin's lymphoma of the testis.

A. Crellin, G. Hudson, M. Bennett, 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

The significance of MALT histology in thyroid lymphoma: a review of patients from the BNLI and Royal Marsden Hospital.

R. Laing, K. Maclennan, P. Hoskin, 1994, Clinical oncology (Royal College of Radiologists (Great Britain)).

Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study.

D C Linch, K. Maclennan, D. Cunningham, 1996, Blood.

Primary gastrointestinal non-Hodgkin's lymphoma: a review of 175 British National Lymphoma Investigation cases.

K. Maclennan, M. Leyland, G. Vaughan Hudson, 1993, British Journal of Cancer.

A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation report.

K. Maclennan, W. Gregory, D. Linch, 1996, British Journal of Cancer.

Soviet-American cooperation on fundamental problems in environmental health.

A. Swerdlow, B. Hudson, G. V. Hudson, 1976, Environmental health perspectives.

Diagnosis and grading of nodular sclerosing Hodgkin's disease: a study of 2190 patients.

K. Maclennan, G. Vaughan Hudson, B. Vaughan Hudson, 1992, International review of experimental pathology.

Clinical stage 1 non-Hodgkin's lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy.

K. Maclennan, D. Linch, G. Vaughan Hudson, 1994, British Journal of Cancer.

Risk of second primary cancer after Hodgkin's disease in patients in the British National Lymphoma Investigation: relationships to host factors, histology and stage of Hodgkin's disease, and splenectomy.

K. Maclennan, A. Swerdlow, A. Douglas, 1993, British Journal of Cancer.

Long-term survival in Hodgkin's disease patients. A comparison of relative survival in patients in trials and those recorded in population-based cancer registries.

A. Swerdlow, J. Estève, P. Roy, 2000, European journal of cancer.

British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease--long term results.

K. Maclennan, J. Haybittle, B. Hancock, 1991, British Journal of Cancer.